{
  "id": "621eb93b3a8413c65300005b",
  "type": "list",
  "question": "List the drug targets of Faricimab?",
  "ideal_answer": "Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34511878",
    "http://www.ncbi.nlm.nih.gov/pubmed/30905643",
    "http://www.ncbi.nlm.nih.gov/pubmed/32785136",
    "http://www.ncbi.nlm.nih.gov/pubmed/31513439",
    "http://www.ncbi.nlm.nih.gov/pubmed/32342814",
    "http://www.ncbi.nlm.nih.gov/pubmed/34188445",
    "http://www.ncbi.nlm.nih.gov/pubmed/32729897",
    "http://www.ncbi.nlm.nih.gov/pubmed/32729888",
    "http://www.ncbi.nlm.nih.gov/pubmed/33471572"
  ],
  "snippets": [
    {
      "text": "Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31513439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511878",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Faricimab is a bispecific antibody that has been developed as an inhibitor of both VEGF and Ang2 that has shown positive results in phase I, II and III trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511878",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Faricimab is a promising bispecific drug targeting VEGF-A and the Ang-Tie/pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33471572",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33471572",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Clinical studies have identified faricimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2 and VEGF-A for treatment of diabetic eye disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32785136",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32342814",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Faricimab is a bispecific anti-VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12- or 16-week dosing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34188445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance: Faricimab, the first bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2 (Ang-2) and vascular endothelial growth factor A ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32729888",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "gimen. Faricimab is a promising bispecific drug targeting VEGF-A and the Ang-Tie/",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33471572",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ntified faricimab, a novel bispecific antibody designed for intravitreal use, to simultaneously bind and neutralize Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both Ang-2 a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32785136",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30905643",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Areas covered: Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2, is in phase 3 trials fo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31513439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "c anti-VEGF/Ang-2 antibody that upregulates the Tie-2 signaling pathway and promotes vascular stability; it is undergoing phase 3 trials with potential for 12- or 16-week dosing. PAN-90806 is a topical ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34188445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31513439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "By targeting both Ang-2 and vascular endothelial growth factor-A (VEGF-A), faricimab displays an improved and sustained efficacy over longer treatment intervals, delivering superior vision outcomes for patients with diabetic macular edema and reducing the treatment burden for patients with neovascular age-related macular degeneration and diabetic macular edema.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32785136",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME).DESIGN: The BOULEVARD trial (ClinicalTrials.gov identifier, NCT02699450) was a prospective, randomized, active comparator-controlled, double-masked, multicenter, phase 2 study conducted at 59 sites in the United States.PARTICIPANTS: The trial enrolled patients 18 years of age or older with center-involving DME, best-corrected visual acuity (BCVA) of 73 to 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) of 325 \u03bcm or more.METHODS: Anti-VEGF treatment-na\u00efve patients were randomized 1:1:1 to intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3 mg ranibizumab, and patients previously treated with anti-VEGF were randomized 1:1 to",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30905643",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance: Faricimab, the first bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A).Objective: To assess the efficacy and safety of different doses and regimens of faricimab vs ranibizumab in patients with neovascular age-related macular degeneration (nAMD).Design, Setting, and Participants: AVENUE was a 36-week, multiple-dose-regimen, active comparator-controlled, double-masked, phase 2 randomized ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32729888",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance: Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous and independent binding.Objective: To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use, in patients with neovascular age-related macular degeneration.Design, Setting, and Participants: This phase 2 randomized clinical trial was a 52-week multic",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32729897",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "VEGF-A, Ang-2"
}